|1.||Yamamoto, Setsuko: 1 article (02/2002)|
|2.||Ohashi, Naohito: 1 article (02/2002)|
|3.||Sasabe, Masao: 1 article (02/2002)|
|4.||Matsui, Kazuki: 1 article (02/2002)|
|5.||Matsui, K: 1 article (10/2000)|
|6.||Kitano, M: 1 article (10/2000)|
|7.||Sasabe, M: 1 article (10/2000)|
|8.||Yamamoto, S: 1 article (10/2000)|
|9.||Ohashi, N: 1 article (10/2000)|
10/01/2000 - "SMP-300 concentration-dependently inhibited recovery from acidosis in rat myocytes, and its IC50 for Na+/H+ exchange was 6 nM. In comparison, its IC50s for Na+/Ca2+ exchange and for the Na+ channel were >1000 nM, and those for other channels or receptors tested were >10,000 nM. In rat isolated perfused hearts, SMP-300 (10(-8)-10(-7) M), administered only at preischemia and not during reperfusion, significantly improved the postischemic recovery of cardiac function. "
|2.||Myocardial Ischemia (Ischemic Heart Diseases)
02/01/2002 - "Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats."
02/01/2002 - "SMP-300 (1 mg/kg, p.o.) reduced myocardial infarct size after 40 min of coronary artery occlusion followed by 24 h of reperfusion, but nifedipine (3 mg/kg, p.o.) or propranolol (100 mg/kg, p.o.) did not. "
02/01/2002 - "The effects of SMP-300, an orally active, potent, and selective Na+/H+ exchange inhibitor, were evaluated and compared with those of nifedipine, propranolol, and nicorandil on three experimental angina models and on myocardial infarction in rats. "
|1.||Nicorandil (SG 75)